Furthermore, the advanced analysis of novel mutations, such as analysis of BTK by flow cytometry, immunofluorescence staining, and/or Western blotting, was not performed, which may weaken the comprehensive understanding of XLA patients. The gene discussed is BTK; the disease is Bruton-type agammaglobulinemia.